mexiletine has been researched along with Polyneuropathies in 1 studies
Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.
Polyneuropathies: Diseases of multiple peripheral nerves simultaneously. Polyneuropathies usually are characterized by symmetrical, bilateral distal motor and sensory impairment with a graded increase in severity distally. The pathological processes affecting peripheral nerves include degeneration of the axon, myelin or both. The various forms of polyneuropathy are categorized by the type of nerve affected (e.g., sensory, motor, or autonomic), by the distribution of nerve injury (e.g., distal vs. proximal), by nerve component primarily affected (e.g., demyelinating vs. axonal), by etiology, or by pattern of inheritance.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barohn, RJ | 1 |
| Gajewski, B | 1 |
| Pasnoor, M | 1 |
| Brown, A | 1 |
| Herbelin, LL | 1 |
| Kimminau, KS | 1 |
| Mudaranthakam, DP | 1 |
| Jawdat, O | 1 |
| Dimachkie, MM | 1 |
| Iyadurai, S | 1 |
| Stino, A | 1 |
| Kissel, J | 1 |
| Pascuzzi, R | 1 |
| Brannagan, T | 1 |
| Wicklund, M | 1 |
| Ahmed, A | 1 |
| Walk, D | 1 |
| Smith, G | 1 |
| Quan, D | 1 |
| Heitzman, D | 1 |
| Tobon, A | 1 |
| Ladha, S | 1 |
| Wolfe, G | 1 |
| Pulley, M | 1 |
| Hayat, G | 1 |
| Li, Y | 1 |
| Thaisetthawatkul, P | 1 |
| Lewis, R | 1 |
| Biliciler, S | 1 |
| Sharma, K | 1 |
| Salajegheh, K | 1 |
| Trivedi, J | 1 |
| Mallonee, W | 1 |
| Burns, T | 1 |
| Jacoby, M | 1 |
| Bril, V | 1 |
| Vu, T | 1 |
| Ramchandren, S | 1 |
| Bazant, M | 1 |
| Austin, S | 1 |
| Karam, C | 1 |
| Hussain, Y | 1 |
| Kutz, C | 1 |
| Twydell, P | 1 |
| Scelsa, S | 1 |
| Kushlaf, H | 1 |
| Wymer, J | 1 |
| Hehir, M | 1 |
| Kolb, N | 1 |
| Ralph, J | 1 |
| Barboi, A | 1 |
| Verma, N | 1 |
| Ahmed, M | 1 |
| Memon, A | 1 |
| Saperstein, D | 1 |
| Lou, JS | 1 |
| Swenson, A | 1 |
| Cash, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS)[NCT02260388] | Phase 4 | 402 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Higher scores for fatigue represents worse outcome (more fatigue). T-score metric: 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population.~On the T-score metric: A score of 40 is one SD lower than the mean of the reference population; A score of 60 is one SD higher than the mean of the reference population." (NCT02260388)
Timeframe: 12 Weeks
| Intervention | T-Score (Mean) |
|---|---|
| Nortriptyline | 53.6 |
| Duloxetine | 55.4 |
| Pregabalin | 56.7 |
| Mexiletine | 51.6 |
"Higher scores for pain interference represents worse outcome (more pain interference) T-score metric: 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population.~On the T-score metric: A score of 40 is one SD lower than the mean of the reference population; A score of 60 is one SD higher than the mean of the reference population." (NCT02260388)
Timeframe: 12 weeks
| Intervention | T-Score (Mean) |
|---|---|
| Nortriptyline | 56.4 |
| Duloxetine | 56.5 |
| Pregabalin | 60.0 |
| Mexiletine | 54.5 |
"Higher scores for sleep disturbance represents worse outcome (more sleep disturbance).~T-score metric: 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population.~On the T-score metric: A score of 40 is one SD lower than the mean of the reference population; A score of 60 is one SD higher than the mean of the reference population.~Higher scores equals more of the concept being measured" (NCT02260388)
Timeframe: 12 weeks
| Intervention | T-Score (Mean) |
|---|---|
| Nortriptyline | 58.9 |
| Duloxetine | 58.9 |
| Pregabalin | 58.3 |
| Mexiletine | 59.1 |
"SF-12v2® Health Survey Standard The Optum™ SF-12v2® Health Survey is a shorter version of the SF-36v2® Health Survey that uses just 12 questions to measure functional health and well-being from the patient's point of view.~Survey provides psychometrically-based physical component summary (PCS) and mental component summary (MCS) scores.~Scores are calibrated so that 50 is the average score or norm, standard deviation = 10.~Higher scores indicate better health for both mental and physical component summary scores." (NCT02260388)
Timeframe: 12 weeks
| Intervention | Norm-Based Standardization Score (Mean) | |
|---|---|---|
| Mental Component Score | Physical Component Score | |
| Duloxetine | 50.9 | 42.1 |
| Mexiletine | 51.3 | 43.7 |
| Nortriptyline | 51.0 | 42.8 |
| Pregabalin | 47.2 | 40.0 |
1 trial available for mexiletine and Polyneuropathies
| Article | Year |
|---|---|
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized Trial.
Topics: Adult; Aged; Analgesics; Bayes Theorem; Comparative Effectiveness Research; Duloxetine Hydrochloride | 2021 |